Malignancies in rheumatoid arthritis (RA) clinical trials with adalimumab (HUMIRATM).

被引：0
|
作者：
Schiff, MH
Gelhorn, AJ
Chartash, E
Fischkoff, SA
机构：
[1] Denver Arthrit Clin, Denver, CO USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Parsippany, NJ USA
来源：
ARTHRITIS AND RHEUMATISM | 2003年 / 48卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1832
引用
收藏
页码：S700 / S700
页数：1
相关论文
共 50 条
  • [1] Injection-site reactions in adalimumab rheumatoid arthritis (RA) pivotal clinical trials
    Wells, AF
    Kupper, H
    Fischkoff, S
    Chartash, E
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 411 - 411
  • [2] Rates of serious infections from adalimumab (HUMIRA®) clinical trials of patients with Rheumatoid Arthritis (RA)
    Kent, J. D.
    Pangan, A. L.
    Spencer-Green, G. T.
    Szczerbak, N.
    Sasso, E. H.
    [J]. RHEUMATOLOGY, 2006, 45 : I42 - I43
  • [3] Rates of infection in adalimumab rheumatoid arthritis clinical trials
    Schiff, M
    Van de Putte, LB
    Breedveld, FC
    Kupper, H
    Fischkoff, S
    Chartash, E
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 184 - 184
  • [4] Attitudes of patients with rheumatoid arthritis (RA) to clinical trials
    Garrood, T.
    Farrow, S.
    Scott, D. L.
    Choy, E. H. S.
    [J]. RHEUMATOLOGY, 2001, 40 : 30 - 30
  • [5] A comparison of the SDAI and DAS28 as measures of response in adalimumab (HUMIRA™) clinical trials in rheumatoid arthritis (RA).
    Smolen, JS
    Breedveld, FC
    Schiff, MH
    Kalden, JR
    Emery, P
    Gelhorn, AJ
    Spencer-Green, GT
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S107 - S107
  • [6] Adalimumab dose escalation improves clinical responses in patients with rheumatoid arthritis (RA)
    Karpouzas, George A.
    Moran, Rosalinda
    Khanna, Dinesh
    Louie, James
    Paulus, Harold
    Furst, Daniel
    Cooray, Dilrukshie
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S537 - S537
  • [7] Early clinical response in venezuelan patients with rheumatoid arthritis (RA) treated with adalimumab
    Pena, N.
    Briceno, F.
    Franco, L. M.
    Herrera, J. A.
    Marin, F.
    Millan, A.
    Paul-Moya, H.
    Perez, P.
    Rodriguez, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 496 - 497
  • [8] Adalimumab safety in Crohn's disease and rheumatoid arthritis clinical trials, reduced mortality in rheumatoid arthritis
    Burmester, G. R.
    Panaccione, R.
    Kent, J. D.
    Pangan, A. L.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S452 - S453
  • [9] Global safety in adalimumab (HUMIRA®) rheumatoid arthritis clinical trials.
    Schiff, MH
    Burmester, GR
    Pangan, AL
    Kupper, H
    Spencer-Green, GT
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S562 - S562
  • [10] Safety of adalimumab (HUMIRA®) in global clinical trials of patients with early vs. long-standing rheumatoid arthritis (RA)
    Schiff, MH
    Burmester, GR
    Pangan, AL
    Kupper, H
    Spencer-Green, GT
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 422 - +
12345